Protalix up on accelerated growth plan

• Protalix BioTherapeutics (NYSE:PLX) jumps 10% premarket on increased volume in response to its announcement of a plan to accelerate its growth by focusing on products with clinically superior profiles including PRX-102 for Fabry disease, PRX-106 for inflammatory bowel disease, PRX-110 for cystic fibrosis and PRX-112 for Gaucher disease.